MRKR VS AIH Stock Comparison

PerformanceTechnicalsEarningsProfitVolatility
PerformanceTechnicalsEarningsProfitVolatility

Performance

MRKR
10/100

MRKR returned -20.79% in the last 12 months. Based on SPY's performance of -13.80%, its performance is below average giving it a score of 10 of 100.

AIH
10/100

AIH returned -60.35% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Technicals

MRKR
21/100

MRKR receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

AIH
11/100

AIH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

MRKR
10/100

MRKR has missed earnings 6 times in the last 20 quarters.

AIH
10/100

AIH has missed earnings 4 times in the last 20 quarters.

Profit

MRKR
10/100

Out of the last 20 quarters, MRKR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AIH
22/100

Out of the last 20 quarters, AIH has had 6 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

MRKR
58/100

MRKR has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

AIH
59/100

AIH has had a higher than average amount of volatility over the last 12 months giving it a score of 59 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Marker Therapeutics, Inc. Common Stock Summary

Nasdaq / MRKR
Healthcare
Biotechnology
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Aesthetic Medical International Holdings Group Ltd. American Depositary Shares Summary

Nasdaq / AIH
Healthcare
Medical - Care Facilities
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 15 treatment centers in China, Hong Kong, and Singapore. Aesthetic Medical International Holdings Group Limited was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.